anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A cosmetic and/or hygienic remedy comprising lactoserum and other usual special ingredients characterised in that it additionally comprises catamin AB in the following ratio % by weight: Lactoserum 10-80 Catamin AB (aqueous solution of alkyldimethylbenzylammonium chloride) 0,1-1,6 Special ingredients the rest 2. A hygienic remedy according to claim 1, characterised in that it is a soap and it additionally comprises a surface-active material (SAM) in the following ratio % by weight: Lactoserum 20-80 catamin AB 0,4-1,6 mixture of SAM 30-60 special ingredients the rest 3. A soap according to claim 2, characterised in that it comprises chitosan succinate (or chitosan) in the amount, % by weight: 0,5-1,0 as a special ingredient. 4. A soap according to claim 2, characterised in that it comprises pyrethrum in the amount, % by weight: 0,6-0,8 as a special ingredient. 5. A hygienic remedy according to claim 1, characterised in that it is a shampoo and it additionally comprises a surface-active material (SAM) in the following ratio % by weight: lactoserum 20-80 catamin AB 0,1-1,6 mixture of SAM 12,8-35,0 special ingredients the rest 6. A shampoo according to claim 5, characterised in that it comprises pyrethrum in the amount, % by weight: 0,6-0,75 as a special ingredient. 7. A shampoo according to claim 5, characterised in that it comprises chitosan succinate (or chitosan) in the amount, % by weight: 0,5-1,0 as a special ingredient. 8. A cosmetic remedy according to claim 1, characterised in that it is a balsam with the following ratio % by weight: lactoserum 10-80 catamin AB 0,6-0,9 special ingredients the rest 9. A balsam according to claim 8, characterised in that it comprises chitosan succinate (or chitosan) in the amount, % by weight: 0,5-1,0 as a special ingredient. 10. A balsam according to claim 8, characterised in that it additionally comprises antihypoxant in the amount, % by weight: 1,0-10,0. 11. A cosmetic-prophylactic remedy according to claim 1, characterised in that it is a cream with the following ratio % by weight: lactoserum 10-50 catamin AB 0,1-0,6 special ingredients the rest 12. A cream according to claim 11, characterised in that it additionally comprises superoxidedismutase in the amount, % by weight: 0,03-1. 13. A cream according to claim 11, characterised in that it additionally comprises antihypoxant in the amount, % by weight: 1,0-10,0. 14. A cream according to claim 11, characterised in that it comprises chitosan succinate in the amount, % by weight: 0,5-3,0 as a special ingredient. 15. A hygienic remedy according to claim 1, characterised in that it is a bath foam in the following ratio % by weight: lactoserum 10-60 catamin AB 0,6-1,6 special ingredients the rest 16. A bath foam according to claim 15, characterised in that it comprises chitosan succinate in the amount, % by weight: 0,5 as a special ingredient. 17. A soap according to claim 2, characterised in that it comprises as a special ingredients, % by weight: chitosan succinate 0,5-1,0 pyrethrum 0,6-0,8. 18. A shampoo according to claim 5, characterised in that it comprises as a special ingredients, % by weight: chitosan succinate 0,5-1,0 pyrethrum 0,6-0,8.
Periodontitis patients treated by means of Q-SI. Patients were treated with non-surgical quadrantwise periodontal treatment in 4 sessions, 1 session per week.
We describe a human lung disease caused by autosomal recessive, complete deficiency of the monocyte chemokine receptor C-C motif chemokine receptor 2 (CCR2). Nine children from five independent kindreds have pulmonary alveolar proteinosis (PAP), progressive polycystic lung disease, and recurrent infections, including bacillus Calmette Guérin (BCG) disease. The CCR2 variants are homozygous in six patients and compound heterozygous in three, and all are loss-of-expression and loss-of-function. They abolish CCR2-agonist chemokine C-C motif ligand 2 (CCL-2)-stimulated Ca2+ signaling in and migration of monocytic cells. All patients have high blood CCL-2 levels, providing a diagnostic test for screening children with unexplained lung or mycobacterial disease. Blood myeloid and lymphoid subsets and interferon (IFN)-γ- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-mediated immunity are unaffected. CCR2-deficient monocytes and alveolar macrophage-like cells have normal gene expression profiles and functions. By contrast, alveolar macrophage counts are about half. Human complete CCR2 deficiency is a genetic etiology of PAP, polycystic lung disease, and recurrent infections caused by impaired CCL2-dependent monocyte migration to the lungs and infected tissues.
Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
RATIONALE: Alpha-lipoic acid is an essential cofactor for aerobic metabolism and acts as a potent antioxidant in the body. It has been shown that acute exposure to methamphetamine induces oxidative stress, which is responsible for severe cognitive deficits in animals. The hippocampus plays a crucial role in the processing of memory and anxiety-like behavior.
OBJECTIVES: In this study, preventive effect of the alpha-lipoic acid on memory impairment in methamphetamine-induced neurotoxicity was investigated.
METHODS: Wistar male rats (200-220 g) were allocated to five groups (seven rats in each group): (1) saline + saline, (2) saline + vehicle (sunflower oil as alpha-lipoic acid solvent), (3) methamphetamine + vehicle, (4) methamphetamine + alpha-lipoic acid 10 mg/kg, and (5) methamphetamine + alpha-lipoic acid 40 mg/kg. Rats received intraperitoneal methamphetamine repeatedly (2 × 20 mg/kg, 2 h interval). Alpha-lipoic acid was injected 30 min, 24 h, and 48 h after the last injection of methamphetamine. The passive avoidance test and open field were used for evaluation of memory retrieval and anxiety, respectively. After behavioral test, rats were anesthetized, their brains were extracted, and after preparing hippocampal homogenates, malondialdehyde (MDA) level, catalase, and superoxide dismutase (SOD) activities were evaluated.
RESULTS: Statistical analysis showed that injection of saline or sunflower oil had no significant effect on anxiety, memory, or oxidative stress markers. Methamphetamine induced memory impairment, increased anxiety-like behavior and MDA level, but it reduced catalase and SOD activity. Treatment with alpha-lipoic acid decreased MDA, increased catalase and SOD activity, and also prevented memory impairment and anxiety-like behavior. Our results showed that alpha-lipoic acid protected the hippocampus from oxidative stress by elevating SOD and CAT activities and reduced memory impairment following acute methamphetamine injection. These findings suggest that alpha-lipoic acid may have a protective effect against the adverse effects of methamphetamine exposure on the hippocampus. Therefore, the current data indicated that ALA can reduce oxidative stress predominantly by its antioxidant property.
The objective of the present study was to comprehensively evaluate whether body measurement traits, including body weight and body size, could be used as indicators of genetic selection for feed efficiency and carcass traits in Japanese Black steers. First, we estimated the genetic parameters for body measurements, feed efficiency, and carcass traits. Second, we estimated the correlated responses in feed efficiency and carcass traits when selection was applied to one or multiple-body measurement traits. In total, 4,578 Japanese Black steers with phenotypic values of residual feed intake (RFI) and residual body weight gain (RG) as feed efficiency traits and carcass weight (CWT) and beef marbling standard (BMS) as carcass traits were used. Eleven body measurement traits were measured at the start and finish of the fattening periods (BMT1 and BMT2, respectively), and their growth during the fattening period (BMT3) was used for genetic analyses. The results of genetic parameters showed that the heritability estimates were low to moderate (0.10 to 0.66), and the genetic correlations among body measurement traits were also estimated to be positively moderate to high in each measuring point (0.23 to 0.99). The genetic correlations of body measurement traits with RFI and BMS were estimated to be low (-0.14 to 0.30 and -0.17 to 0.35, respectively), but those with CWT were positively low to high (0.12 to 0.97). The genetic correlation estimates between BMT3 and RG were moderate to high (0.38 to 0.78). Second, correlated responses were estimated under positive selection for body measurement traits. Positive selection for BMT2 and BMT3 increased CWT and RG; however, positive selection for body measurement traits resulted in no change in RFI and BMS. Favorable directions of genetic gains, which were positive for RG, CWT, and BMS and negative for RFI, were obtained by selection indices, including multiple traits in BMT1. Our results suggest that using only one-body measurement trait as an indicator of genetic selection for RFI is difficult. However, body measurement traits can be indirect indicators of improved RG. Our results also suggest that genetic improvement of both RFI and RG without reducing CWT and BMS could be achieved using selection indices that account for a balance of body conformation using multiple-body measurement traits in Japanese Black cattle.
Systems and methods for managing illness outside of a hospital environment are provided. A  plurality of alert generation definitions is stored with each of the definitions defining at least one condition for generating an alert. A patient profile data structure for a patient is generated which includes indicators of characteristics of the patient. Monitoring data is received, which reflects at least one of (i) physiological indicators of the patient; and (ii) indicators of medical supplies being ordered or consumed by the patient. An alert relating to patient healthcare is generated by applying at least one of the alert generation definitions to the received monitoring data.  Population data reflective of healthcare outcomes for a patient population is received. At least one further alert generation definition is generated upon processing the population data, and the at least one further alert generation definition is stored.
A 69-year-old man presented with lumbago and was diagnosed with multiple myeloma (IgD-λ type, R-ISS stage II) with bone-destructive lesions in the lumbar spine and sacrum. Chromosome analysis showed t (8;14)(q24;q32) and t (11;14)(q13;q32). Treatment with daratumumab, lenalidomide, and dexamethasone resulted in partial response, but the disease relapsed, with a copy number increase in t (11;14) and abnormal amplification of the 1q21 region. The patient was treated for CMV enteritis, and was admitted to the hospital due to sudden abdominal pain. Gastrointestinal perforation was diagnosed by CT scan showing free air and wall thickening in the small intestine. Emergency surgery was performed, and the tumors in the perforated area were positive for CCND1 but negative for MYC on immunostaining. The patient's general condition did not improve after the surgery and he died. Pathological autopsy revealed extramedullary infiltration of multiple organs in addition to the small intestine. Extramedullary infiltration is thought to be caused by clonal evolution, and further research is warranted to clarify its pathogenesis and establish effective therapeutic strategies in high-risk patients.
The present invention relates to a medicine, particularly to a method for preparing medicated liquor for treating rheumatic and rheumatoid diseases. The medicine comprises the following Chinese herbal medicines of the compositions: 3 to 5g of ginseng, 3 to 5g of gastrodia tuber, 5 to 10g of prepared rhizome of rehmannia, and 2 to 4g of panax notoginseng. The preparation method comprises the following steps: baking the Chinese herbal medicines by a drying tank; crushing the Chinese herbal medicines into fine powder; sieving; blending the fine powder according to a proportion; packaging the fine powder into medicine bags by cloth bags; placing the fine powder in 220 to 280g of 50 to 60 Vol% liquor for immersion; and taking the medicine bags. Proved by large amounts of clinical application, the medicated liquor of the medicine can cure diseases, such as rheumatic and rheumatoid diseases, cerebral arteriosclerosis, apoplexy, arthromyodynia of limbs, hyperosteogeny, traumatic injuries, etc. The patients with the diseases can be cured in a short time by 2 to 3 times of oral administration per day, and 20 to 30g of medicine is taken every time; the medicine also has obvious curative effect in external application. The medicine has the advantages of short treatment course, good curative effect, no toxic or side effect, wide medicine source and simple preparation technology.
This study will pilot and test feasibility of a prenatal lifestyle intervention designed to limit gestational weight gain and prevent gestational diabetes. The intervention is based on the Diabetes Prevention Program lifestyle intervention, will include prenatal breastfeeding education and online peer group support, and will be integrated into the participants' regular prenatal appointments. Women (n=24) will be enrolled in early pregnancy. After baseline assessments (demographics, maternal diet, physical activity, mental health), women randomized equally to the intervention or usual care conditions. Further data collection will occur at approximately 24 weeks gestation, 36 weeks gestation, and 6 weeks postpartum, and clinical data (weight, pregnancy and obstetric complications) will be abstracted from medical records at the end of the study. Outcomes include reach and dose of the intervention, gestational weight gain, dietary intake, physical activity, and breastfeeding in the first 6 weeks postpartum. The investigators hypothesize that the intervention will reduce gestational weight gain, improve maternal dietary intake, increase total energy expenditure, and increase breastfeeding exclusivity in the first 6 weeks postpartum.
Provided are liposomes including a lipid membrane enclosing an intraliposomal compartment. The liposomes may encapsulate an iron complex, including an iron moiety and a macromolecule, in the intraliposomal compartment. The liposomes may additionally have a targeting moiety associated with the liposomal membranes. The targeting moiety may be exposed at the liposome's outer surface. The liposomes exhibit an immunomodulatory effect or anti-cancer effect depending on the molar ratio between the lipids forming the lipid membrane and the iron complex. As such, the liposomes can be used to treat types of inflammation, particularly inflammations that are not associated or caused by infection or be used to treat cancer. Further provided are compositions including the disclosed liposomes, methods of using and kits including the liposomes.
BACKGROUND: Motile Sperm Domain-Containing Protein 1 (MOSPD1) has been implicated in breast cancer (BC) pathophysiology, but its exact role remains unclear. This study aimed to assess MOSPD1 expression levels in BC versus normal tissues and investigate its diagnostic potential.
METHODS: MOSPD1 expression was analyzed in BC and normal tissues, with Receiver Operating Characteristic analysis for diagnostic evaluation. Validation was performed using immunohistochemistry. Functional studies included tumor growth assays, MOSPD1 suppression and overexpression experiments, and testing BC cell responses to anti-PD-L1 therapy.
RESULTS: MOSPD1 expression was significantly higher in BC samples than normal tissues, correlating with poor clinical outcomes in BC patients. MOSPD1 suppression inhibited tumor growth, while overexpression accelerated it. Silencing MOSPD1 enhanced BC cell sensitivity to anti-PD-L1 therapy and decreased Th2 cell activity. In vivo experiments supported these findings, showing the impact of MOSPD1 on tumor growth and response to therapy.
CONCLUSIONS: Elevated MOSPD1 levels in BC suggest its potential as a biomarker for adverse outcomes. Targeting MOSPD1, particularly with anti-PD-L1 therapy, may effectively inhibit BC tumor growth and modulate immune responses. This study emphasizes the significance of MOSPD1 in BC pathophysiology and highlights its promise as a therapeutic target.
BACKGROUND: Subarachnoid hemorrhage (SAH), a severe subtype of stroke, is characterized by notably high mortality and morbidity, largely due to the lack of effective therapeutic options. Although the neuroprotective potential of PPARg and Nrf2 has been recognized, investigative efforts into oroxin A (OA), remain limited in preclinical studies.
METHODS: SAH was modeled in vivo through filament perforation in male C57BL/6 mice and in vitro by exposing HT22 cells to hemin to induce neuronal damage. Following the administration of OA, a series of methods were employed to assess neurological behaviors, brain water content, neuronal damage, cell ferroptosis, and the extent of neuroinflammation.
RESULTS: The findings indicated that OA treatment markedly improved survival rates, enhanced neurological functions, mitigated neuronal death and brain edema, and attenuated the inflammatory response. These effects of OA were linked to the suppression of microglial activation. Moreover, OA administration was found to diminish ferroptosis in neuronal cells, a critical factor in early brain injury (EBI) following SAH. Further mechanistic investigations uncovered that OA facilitated the translocation of nuclear factor erythroid 2-related factor 2 (Nrf-2) from the cytoplasm to the nucleus, thereby activating the Nrf2/GPX4 pathway. Importantly, OA also upregulated the expression of FSP1, suggesting a significant and parallel protective effect against ferroptosis in EBI following SAH in synergy with GPX4.
CONCLUSION: In summary, this research indicated that the PPARg activator OA augmented the neurological results in rodent models and diminished neuronal death. This neuroprotection was achieved primarily by suppressing neuronal ferroptosis. The underlying mechanism was associated with the alleviation of cellular death through the Nrf2/GPX4 and FSP1/CoQ10 pathways.
Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
Pulmonary embolism (PE) is a worldwide health problem, with an estimated incidence of up to 69 cases per 100,000 persons annually. In the U.S., 101,000 patients were hospitalized with a primary diagnosis of PE in 2002, resulting in direct medical costs of $720 million. There is growing evidence that outpatient treatment with low-molecular-weight heparin (LMWH) is an effective and safe option for up to 50% of patients with non-massive PE. Despite this evidence, outpatient treatment of PE is uncommon because (1) explicit criteria that identify patients who are at low-risk of adverse medical outcomes have not been available, and (2) randomized trials demonstrating the effectiveness and safety of outpatient treatment have not been performed. We developed a clinical prognostic model that accurately identifies patients with PE who are at low-risk for short-term mortality, symptomatic recurrent venous thromboembolism (VTE), and major bleeding. This model provides clinicians an easily applied, explicit risk stratification tool for patients with PE, addressing a key barrier to outpatient treatment. The broad objective of this clinical trial is to address the other major barrier to outpatient treatment of low-risk patients with non-massive PE, the effectiveness and safety of outpatient management. We will randomize low-risk patients (identified using our prognostic model) with PE from hospital emergency departments to receive outpatient or inpatient treatment with LMWH for ≥5 days, followed by oral anticoagulation. The specific aims of the project are to compare (1) the frequency of recurrent VTE, (2) the frequency of major bleeding and all-cause mortality, and (3) medical resource utilization and patient satisfaction with care among patients randomized to receive outpatient or inpatient treatment with LMWH. The primary study outcome will be the rate of symptomatic recurrent VTE at 3 months after randomization. The secondary outcomes will be the rate of major bleeding and all-cause mortality. The ancillary outcomes will be medical resource utilization and patient satisfaction with care. The hypotheses guiding this trial are that outpatient treatment with LMWH is as effective and safe as inpatient treatment with LMWH, and is also associated with reduced medical resource utilization and increase patient satisfaction with care. This study is innovative because it translates a validated prognostic model into clinical practice and represents the first direct comparison of outpatient versus inpatient treatment of low-risk patients with PE. Successful completion of this project will provide a strong scientific basis for treating low-risk patients with PE in the outpatient setting. Outpatient management of low-risk patients with PE is likely to improve quality and efficiency of care by reducing resource utilization and increasing patient satisfaction with care. Our findings will have importance to physicians, hospitals, and policy-makers who are committed to optimizing patient safety and providing high-quality, cost-effective care.
PURPOSE: An aminopyrimidine-based derivative which suppresses PI3K beta and a PI3K beta inhibitor composition containing the same are provided to ensure excellent activity to PI3K beta with high selectivity and to treat diseases related to PI3K beta. CONSTITUTION: An aminopyrimidine-based derivative or a pharmaceutically acceptable salt thereof is denoted by chemical formula 3. The pharmaceutically acceptable salt is non-toxic acid addition salts, basic addition salts, metal salts, amino acid salts, or organic salts containing pharmaceutically acceptable anions. A PI3K beta inhibitor composition contains the aminopyrimidine-based derivative of chemical formula 3 as an active ingredient, and pharmaceutically acceptable carriers or diluents. A method for preparing the aminopyrimidine-based derivative comprises the step of preparing a compound of chemical formula 3 through Suzuki coupling reaction of compounds of chemical formulas 5 and 6. A method for preparing the aminopyrimidine-based derivative comprises the step of treating a compound of chemical formula 8 with R1C1.
BACKGROUND: Left atrial myxoma during pregnancy is rare. We present three cases in order to aid in the management.
CASE PRESENTATION: Three cases of left atrial myxoma during pregnancy were presented in this article. Three patients all received multidisciplinary team work and acquired good outcomes. The case 1 had no symptoms and delivered before traditional cardiac surgery. The case 2 and case 3 undergone totally endoscopic minimally invasive cardiac surgery during pregnancy. The case 3 maintained pregnancy to term and gave birth to a healthy baby via vaginal delivery. No relapse of the tumor was observed.
CONCLUSIONS: The management of left atrial myxoma during pregnancy ought to be individualized and combined with the gestational age. If the diagnosis was made in the first two trimesters of pregnancy, totally endoscopic minimally invasive cardiac surgery during pregnancy would be an optimal choice. The patients can benefit from the multidisciplinary team work.